PRGO Quote, Financials, Valuation and Earnings

Amarin Corp. Plc has a net margin of -127.44% compared to Perrigo Co. Plc's net margin of -2.49%. Perrigo Co. Plc's return on equity of -34.14% beat Amarin Corp. Plc's return on equity of -8.32%.

Perrigo Co. Plc has a consensus price target of $17.00, signalling upside risk potential of 56.68%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -18.23%. Given that Perrigo Co. Plc has higher upside potential than Amarin Corp. Plc, analysts believe Perrigo Co. Plc is more attractive than Amarin Corp. Plc.

Perrigo Co. Plc has a beta of 0.476, which suggesting that the stock is 52.382% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.549%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 10.84%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1.1B, which are larger than Amarin Corp. Plc quarterly revenues of $49.1M. Perrigo Co. Plc's net income of -$1.4B is lower than Amarin Corp. Plc's net income of -$1.2M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.35x versus 1.42x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -127.44% compared to Perrigo Co. Plc's net margin of 16.98%. Perrigo Co. Plc's return on equity of -34.14% beat Jazz Pharmaceuticals Plc's return on equity of -8.79%.

Perrigo Co. Plc has a consensus price target of $17.00, signalling upside risk potential of 56.68%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $223.50 which suggests that it could grow by 19.55%. Given that Perrigo Co. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Perrigo Co. Plc is more attractive than Jazz Pharmaceuticals Plc.

Perrigo Co. Plc has a beta of 0.476, which suggesting that the stock is 52.382% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.231, suggesting its less volatile than the S&P 500 by 76.921%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 10.84%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1.1B, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.2B. Perrigo Co. Plc's net income of -$1.4B is lower than Jazz Pharmaceuticals Plc's net income of $203.5M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.35x versus 2.69x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic Plc has a net margin of -127.44% compared to Perrigo Co. Plc's net margin of 12.75%. Perrigo Co. Plc's return on equity of -34.14% beat Medtronic Plc's return on equity of 9.51%.

Perrigo Co. Plc has a consensus price target of $17.00, signalling upside risk potential of 56.68%. On the other hand Medtronic Plc has an analysts' consensus of $110.60 which suggests that it could grow by 27.67%. Given that Perrigo Co. Plc has higher upside potential than Medtronic Plc, analysts believe Perrigo Co. Plc is more attractive than Medtronic Plc.

Perrigo Co. Plc has a beta of 0.476, which suggesting that the stock is 52.382% less volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.32%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 10.84%. Medtronic Plc offers a yield of 3.26% to investors and pays a quarterly dividend of $0.71 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1.1B, which are smaller than Medtronic Plc quarterly revenues of $9B. Perrigo Co. Plc's net income of -$1.4B is lower than Medtronic Plc's net income of $1.2B. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Medtronic Plc's PE ratio is 24.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.35x versus 3.17x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.

STERIS Plc (Ireland) has a net margin of -127.44% compared to Perrigo Co. Plc's net margin of 12.99%. Perrigo Co. Plc's return on equity of -34.14% beat STERIS Plc (Ireland)'s return on equity of 10.4%.

Perrigo Co. Plc has a consensus price target of $17.00, signalling upside risk potential of 56.68%. On the other hand STERIS Plc (Ireland) has an analysts' consensus of $279.29 which suggests that it could grow by 27.7%. Given that Perrigo Co. Plc has higher upside potential than STERIS Plc (Ireland), analysts believe Perrigo Co. Plc is more attractive than STERIS Plc (Ireland).

Perrigo Co. Plc has a beta of 0.476, which suggesting that the stock is 52.382% less volatile than S&P 500. In comparison STERIS Plc (Ireland) has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.897%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 10.84%. STERIS Plc (Ireland) offers a yield of 1.13% to investors and pays a quarterly dividend of $0.63 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. STERIS Plc (Ireland) pays out 35.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1.1B, which are smaller than STERIS Plc (Ireland) quarterly revenues of $1.5B. Perrigo Co. Plc's net income of -$1.4B is lower than STERIS Plc (Ireland)'s net income of $194.4M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while STERIS Plc (Ireland)'s PE ratio is 30.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.35x versus 3.68x for STERIS Plc (Ireland). Usually stocks with elevated PS ratios are considered overvalued.